The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice
Open accessAbstract
Interleukin-12 (IL-12) is a heterodimeric cytokine produced by antigen-presenting cells that has the ability to induce gamma interferon (IFN-gamma) secretion by T and natural killer cells and to generate normal Th1 responses. These properties suggest that IL-12 may play an important role in the immune response to many viruses, including hepatitis B virus (HBV). Recently, we have shown that HBV-specific cytotoxic T lymphocytes inhibit HBV replication in the livers of transgenic mice by a noncytolytic process that is mediated in part by IFN-gamma. In the current study, we demonstrated that the same antiviral response can be initiated by recombinant murine IL-12 and we showed that the antiviral effect of IL-12 extends to extrahepatic sites such as the kidney. Southern blot analyses revealed the complete disappearance of HBV replicative intermediates from liver and kidney tissues at IL-12 doses that induce little or no inflammation in these tissues. In addition, immunohistochemical analysis demonstrated the disappearance of cytoplasmic hepatitis B core antigen from both tissues after IL-12 treatment, suggesting that IL-12 either prevents the assembly or triggers the degradation of the nucleocapsid particles within which HBV replication occurs. Importantly, we demonstrated that although IFN-gamma, tumor necrosis factor alpha, and IFN-alpha/beta mRNA are induced in the liver and kidney after IL-12 administration, the antiviral effect of IL-12 is mediated principally by its ability to induce IFN-gamma production in this model. These results suggest that IL-12, through its ability to induce IFN-gamma, probably plays an important role in the antiviral immune response to HBV during natural infection. Further, since relatively nontoxic doses of recombinant IL-12 profoundly inhibit HBV replication in the liver and extrahepatic sites in this model, IL-12 may have therapeutic value as an antiviral agent for the treatment of chronic HBV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidotti, L. G., Ando, K., Hobbs, M. V., Ishikawa, T., Runkel, L., Schreiber, R. D., & Chisari, F. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3764 · Cited by 412
Self-citation
Cited by
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,569
Noncytolytic Control of Viral Infections by the Innate and Adaptive ImmuneResponse
Guidotti, L. G., & Chisari, F. V. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.65 · Cited by 996
Self-citationInterleukin-12: A Cytokine at the Interface of Inflammation and Immunity
Trinchieri, G. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60387-9 · Cited by 760
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
Rehermann, B. (2013) · Nature Medicine · doi:10.1038/nm.3251 · Cited by 468
Toll-Like Receptor Signaling Inhibits Hepatitis B Virus Replication In Vivo
Isogawa, M., Robek, M. D., Furuichi, Y., & Chisari, F. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.11.7269-7272.2005 · Cited by 442
Self-citation
Metadata
- Authors
- Cavanaugh, V. J., Guidotti, L. G., & Chisari, F. V.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 1997-04
- Volume
- 71
- Issue
- 4
- Pages
- 3236-3243
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W1933670444
- Cited by
- 237
- References
- 1
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. https://app.cochat.ai/papers/10.1128/jvi.71.4.3236-3243.1997
- The paper
- Cavanaugh, V. J., Guidotti, L. G., & Chisari, F. V. (1997). Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. Journal of Virology. https://doi.org/10.1128/jvi.71.4.3236-3243.1997
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.